Trial Profile
A Study to Evaluate the Efficacy and Safety of Gefitinib as First-line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2015
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms BE-Positive
- 15 Dec 2015 New trial record